GlassScriptPhysician profile
Arnaldo Quintero
NPI 1538564091
$1,362.51
in general payments reported to CMS, 2019-2025
19 companies · $86.18 in 2025
The $86.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,276 · 2025: $86.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279 · Education: $83.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.71 |
| Education | $83.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $234.42 | 2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $154.27 | 2024 | |
| Daiichi Sankyo INC. | $135.12 | 2024 | Enhertu |
| Lilly USA, LLC | $124.53 | 2024 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $107.18 | 2024 | Imfinzi, Calquence |
| Pharmaessentia USA Corporation | $98.81 | 2024 | Besremi |
| Abbvie INC. | $85.94 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $66.52 | 2024 | |
| Janssen Biotech, INC. | $57.30 | 2024-2025 | Erleada, Talvey, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $45.85 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.57 | 2024 | Ninlaro, Iclusig |
| Eisai INC. | $40.35 | 2024 | |
| Sun Pharmaceutical Industries INC. | $39.22 | 2024 | |
| Stemline Therapeutics INC. | $31.89 | 2024 | Orserdu |
| Tersera Therapeutics LLC | $23.90 | 2024 | Zoladex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $22.31 | 2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $19.31 | 2024 | Myrisk |
| Sobi, INC | $17.85 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.17 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnaldo Quintero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.